Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients

January 25, 2021 updated by: Sabahattin Destek, Bezmialem Vakif University

Thyroid Function Tests and the Status of Thyroid Autoantibodies in Hospitalized Covid-19 Patients and Their Relationship With White Blood Cells, Neutrophil / Lymphocyte Ratio, c Reactive Protein, Fibrinogen, Procalcitonin, Ferritin and D-dimer

COVID-19 infection causes a hypersensitive immune reaction and widespread inflammation through cytokines in various organs of the body, especially the lungs.

This cytokine-mediated widespread inflammation can also affect the thyroid gland, causing thyroiditis and impaired thyroid functions.

The researchers evaluated thyroid function tests and thyroid autoantibodies in patients hospitalized for COVID-19 infection. Researchers excluded patients on intensive care therapy and patients with known thyroid disease.

The researchers examined the relationship of thyroid hormones and thyroid autoantibodies to COVID-19 disease, white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, and D-dimer stages in these patients. Researchers compared changes in thyroid hormones and autoantibodies in people without COVID-19 infection and without thyroid disease.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The coronavirus-2 (SARS-COV-2) virus, which can cause severe acute respiratory syndrome through droplet, has caused the global Coronavirus 19 (COVID-19) pandemic. COVID-19 infection can be asymptomatic as well as lead to severe illness and even death. This virus causes a hypersensitive immune reaction and varying degrees of widespread inflammation through cytokines in various organs of the body, mainly the lungs.

Cytokine-mediated widespread inflammation caused by the virus may also affect the thyroid gland and thyrocytes, causing thyroiditis and impairment of thyroid functions. Thus, it may cause changes in thyroid hormones and thyroid autoantibodies.

In study, the researchers found that in patients who were symptomatic with COVID-19 infection and who were hospitalized, thyroid function tests such as serum thyrotropin (TSH), free triiodothyronine (FT3), free thyroxine (FT4) and thyroid peroxidase antibodies (TPOAb), anti-thyroglobulin evaluated antibodies (TGAb). The investigators did not recruit patients in intensive care and patients with known thyroid disease.

Researchers looked at the association of patients' thyroid hormones and thyroid autoantibodies with white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer from hospital archives. The researchers determined how the thyroid hormones and autoantibodies of patients with COVID-19 infection were compared with healthy individuals without COVID-19 infection and thyroid disease.

Study Type

Observational

Enrollment (Actual)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
    • Istanbul
      • Fatih, Istanbul, Turkey, 34093
        • Sabahattin Destek

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

The results of screening thyroid blood tests of healthy people without thyroid disease will be compared with the records of the COVID 19 patient group who were hospitalized and treated with no known thyroid disease.

Description

Inclusion Criteria:

  • To accept research.
  • Being over the age of 18.
  • COVID 19 test results to be positive.
  • Not taking thyroid disease medication before.
  • Receiving inpatient treatment in the COVID service in the hospital.

Exclusion Criteria:

  • Not accepting research.
  • Be under the age of 18.
  • Negative COVID 19 test results for patients.
  • COVID patients treated as outpatient.
  • Thyroid disease in the healthy control group.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Covid Disease Patient Group
Researchers evaluated serum thyrotropin, free triiodothyronine, free thyroxine hormones, thyroid peroxidase antibodies and anti-thyroglobulin antibodies in patients hospitalized for COVID-19 infection. The researchers evaluated the results of white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer in Covid-9 patients.
Diagnostic test: Venous blood was collected for biochemistry testing.
For the measurement of blood tests, 10 ml of blood samples were taken from the right forearm veins with a syringe.
Covid-Free Control Group
Researchers evaluated the results of serum thyrotropin, free triiodothyronine, free thyroxine hormones, thyroid peroxidase antibodies and anti-thyroglobulin antibodies, white blood cells, neutrophil / lymphocyte ratio, c reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer in the non-patient control group.
Diagnostic test: Venous blood was collected for biochemistry testing.
For the measurement of blood tests, 10 ml of blood samples were taken from the right forearm veins with a syringe.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of thyroid stimulating hormone (TSH) between groups
Time Frame: 90 days
In the study, serum TSH results of the Covid patient group and non-Covid control groups were recorded and compared statistically.
90 days
Comparison of free triiodothyronine (fT3) between groups
Time Frame: 90 days
In the study, serum fT3 results of the Covid patient group and non-Covid control groups were recorded and compared statistically.
90 days
Comparison of free thyroxine (fT4) between groups
Time Frame: 90 days
In the study, serum fT4 results of the Covid patient group and non-Covid control groups were recorded and compared statistically.
90 days
Comparison of anti-thyroid peroxidase (Anti-TPO) between groups
Time Frame: 90 days
In the study, serum anti-TPO results of the Covid patient group and non-Covid control groups were recorded and compared statistically.
90 days
Comparison of anti-thyroglobulin (Anti-Tg) between groups
Time Frame: 90 days
In the study, serum anti-Tg results of the Covid patient group and non-Covid control groups were recorded and compared statistically.
90 days
White blood cells (WBC) results of Covid 19 patient group
Time Frame: 90 days
In the study, serum WBC results were recorded in Covid 19 patient groups.
90 days
Neutrophil / lymphocyte ratio (N/LO) results of Covid 19 patient group
Time Frame: 90 days
In the study, serum N/LO results were recorded in Covid 19 patient groups.
90 days
C-reactive protein (CRP) results of Covid 19 patient group
Time Frame: 90 days
In the study, serum CRP results were recorded in Covid 19 patient groups.
90 days
Fibrinogen results of Covid 19 patient group
Time Frame: 90 days
In the study, serum fibrinogen results were recorded in Covid 19 patient groups.
90 days
Procalcitonin results of Covid 19 patient group
Time Frame: 90 days
In the study, serum procalcitonin results were recorded in Covid 19 patient groups.
90 days
Ferritin results of Covid 19 patient group
Time Frame: 90 days
In the study, serum ferritin results were recorded in Covid 19 patient groups.
90 days
D-dimer results of Covid 19 patient group
Time Frame: 90 days
In the study, serum D-dimer results were recorded in Covid 19 patient groups.
90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bezmialem Vakif University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2020

Primary Completion (Actual)

December 5, 2020

Study Completion (Actual)

December 7, 2020

Study Registration Dates

First Submitted

December 7, 2020

First Submitted That Met QC Criteria

December 8, 2020

First Posted (Actual)

December 9, 2020

Study Record Updates

Last Update Posted (Actual)

January 26, 2021

Last Update Submitted That Met QC Criteria

January 25, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 06122020

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

The study will be shared when it becomes an article.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19 Infection

Clinical Trials on Venous blood was collected for biochemistry testing.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe